KR20230157356A - 항-cd30l 항체 및 이의 용도 - Google Patents

항-cd30l 항체 및 이의 용도 Download PDF

Info

Publication number
KR20230157356A
KR20230157356A KR1020237031681A KR20237031681A KR20230157356A KR 20230157356 A KR20230157356 A KR 20230157356A KR 1020237031681 A KR1020237031681 A KR 1020237031681A KR 20237031681 A KR20237031681 A KR 20237031681A KR 20230157356 A KR20230157356 A KR 20230157356A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
set forth
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031681A
Other languages
English (en)
Korean (ko)
Inventor
제시-파라 펙토
마크 렌쇼
요한 프란손
올리비에르 라우렌트
버튼 바넷
Original Assignee
프로메테우스 바이오사이언시즈, 인크.
독토르. 팔크 파르마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메테우스 바이오사이언시즈, 인크., 독토르. 팔크 파르마 게엠베하 filed Critical 프로메테우스 바이오사이언시즈, 인크.
Publication of KR20230157356A publication Critical patent/KR20230157356A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237031681A 2021-02-17 2022-02-16 항-cd30l 항체 및 이의 용도 Pending KR20230157356A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
US63/150,373 2021-02-17
PCT/US2022/016565 WO2022177963A1 (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20230157356A true KR20230157356A (ko) 2023-11-16

Family

ID=82931610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031681A Pending KR20230157356A (ko) 2021-02-17 2022-02-16 항-cd30l 항체 및 이의 용도

Country Status (20)

Country Link
US (3) US20240254246A1 (https=)
EP (1) EP4294840A4 (https=)
JP (2) JP7559257B2 (https=)
KR (1) KR20230157356A (https=)
CN (2) CN118047872A (https=)
AR (1) AR124895A1 (https=)
AU (1) AU2022224561A1 (https=)
BR (1) BR112023016445A2 (https=)
CA (1) CA3208060A1 (https=)
CL (1) CL2023002393A1 (https=)
CO (1) CO2023011962A2 (https=)
CR (1) CR20230445A (https=)
EC (1) ECSP23070234A (https=)
GE (3) GEAP202516710A (https=)
IL (1) IL305146A (https=)
JO (1) JOP20230186A1 (https=)
MX (1) MX2023009621A (https=)
PE (1) PE20231680A1 (https=)
TW (1) TW202302637A (https=)
WO (1) WO2022177963A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
AR133766A1 (es) * 2023-09-12 2025-10-29 Amgen Inc Anticuerpos anti-cd30l y usos de los mismos
WO2025075049A1 (ja) * 2023-10-03 2025-04-10 国立大学法人京都大学 ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69334070T2 (de) * 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
SG11201401536QA (en) * 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
CN117264057A (zh) * 2012-04-27 2023-12-22 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
EP2945865B1 (en) 2013-01-18 2019-01-09 LORD Corporation Active vibration control devices, systems, and methods
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
EP3405185A4 (en) 2016-01-19 2019-09-18 Thomas Blumenthal BIOMARKERS FOR DOWN SYNDROME AND USES THEREOF
ES2962715T3 (es) * 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof

Also Published As

Publication number Publication date
GEAP202416351A (en) 2024-02-12
GEP20257791B (en) 2025-09-10
CL2023002393A1 (es) 2024-03-22
BR112023016445A2 (pt) 2023-12-12
AR124895A1 (es) 2023-05-17
JP7559257B2 (ja) 2024-10-01
EP4294840A1 (en) 2023-12-27
US20240092923A1 (en) 2024-03-21
GEAP202516710A (en) 2025-05-13
CA3208060A1 (en) 2022-08-25
WO2022177963A1 (en) 2022-08-25
US20230060624A1 (en) 2023-03-02
TW202302637A (zh) 2023-01-16
US12516126B2 (en) 2026-01-06
JP2025004013A (ja) 2025-01-14
CN118047872A (zh) 2024-05-17
CN117255802A (zh) 2023-12-19
CR20230445A (es) 2023-11-14
CO2023011962A2 (es) 2023-09-29
AU2022224561A1 (en) 2023-09-28
US11866505B2 (en) 2024-01-09
JOP20230186A1 (ar) 2023-08-09
IL305146A (en) 2023-10-01
PE20231680A1 (es) 2023-10-19
ECSP23070234A (es) 2023-10-31
US20240254246A1 (en) 2024-08-01
AU2022224561A9 (en) 2023-10-05
JP2024509746A (ja) 2024-03-05
MX2023009621A (es) 2023-10-31
EP4294840A4 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
JP7559257B2 (ja) 抗ｃｄ３０ｌ抗体およびその使用
AU2015283270B2 (en) Anti-TNFa antibodies with pH-dependent antigen binding
JP2023505408A (ja) 抗ｔｓｌｐ抗体及びその使用
US20230357420A1 (en) Anti-cd122 antibodies and uses thereof
KR20170049554A (ko) Cd123 결합제 및 그의 용도
WO2016179518A2 (en) Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
RU2758008C2 (ru) Анти-il-5 антитела
AU2016361462A1 (en) CD131 binding proteins and uses thereof
CN115461366A (zh) 抗ox40抗体及其用途
JP2026001077A (ja) Ｉｌ－１３及びｉｌ－１８を標的とする多重特異的抗体
TW202328183A (zh) 人類介白素-4受體α抗體
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
TW202334199A (zh) 特異性結合肺炎克雷伯菌o2抗原和o1抗原的雙特異性抗體以及組合物
US20250243286A1 (en) Antibodies Targeting ActRIIA and ActRIIB
EA052892B1 (ru) Антитела к альфа-рецептору интерлейкина-4 человека
CN121270705A (zh) 抗cMET抗体
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体
EA046142B1 (ru) Антитела к trem-1 и их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230915

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250213

Comment text: Request for Examination of Application